Main menu

Targeted adaptive sampling enables clinical pharmacogenomics testing and genome-wide genotyping


Over 90% of people carry variants that could impact drug efficacy or safety. Here, Peng and Lin et al. validated Oxford Nanopore sequencing for accurate, haplotype-resolved testing of 35 pharmacogenomic targets, achieving high accuracy and enabling genome-wide genotyping — a scalable, cost-effective step towards truly personalised medicine.

Watch Pamela Gan’s talk at London Calling 2025

Sample type: cell lines, human blood

Kit: ligation sequencing kit, native barcoding kit

Authors: Pamela Gan Hui Peng, Yeo Han Lin, Muhammad Irfan Bin Hajis, Yusuf Maulana, Audrey Ng Qi Hui, Kevin Nathanael Ramanto, Marta Nisita Dewanggana, Astrid Irwanto, Levana Sani, Ling Goh Liuh, Mar Gonzalez-Porta

Getting started

Buy a MinION starter pack Nanopore store Sequencing service providers Channel partners

Nanopore technology

Subscribe to Nanopore updates Resources and publications What is the Nanopore Community

About Oxford Nanopore

News Company timeline Sustainability Leadership team Media resources & contacts For investors For partners Working at Oxford Nanopore Current vacancies Commercial information BSI 27001 accreditationBSI 90001 accreditationBSI mark of trust
Spanish flag